Cardiology

Todd Hobbs, MD, chief medical officer at Novo Nordisk North America, discusses what prompted Novo Nordisk to create oral semaglutide.

Todd Hobbs, MD, CMO of Novo Nordisk, discusses the findings of the PIONEER 2 study.

A new study which considered the suggested association between type 2 diabetes and vitamin D deficiency did not show a statistically significant reduction of patient risk.

Investigators found that expansion states had a median of 4.3 fewer deaths per 100,000 residents than nonexpansion states.

Amarin announced the FDA had granted their sNDA for icosapent ethyl to reduce residual CV risk in patients with statin-managed LDL-C cholesterol.

The new occluder, which can repair both small and large cardiovascular defects, received premarket approval.

Analyses of more than 2 million patients found that preterm and early births were associated with an increased risk of ischemic heart disease.

A recent study examines the association between new-onset atrial fibrillation and aortic valve replacements and transcatheter aortic valve implantations.

A study of more than 74,000 in China from 2006 to 2015 found that cardiovascular health scores are associated with subsequent risk of CVD events.

A recent study has found that consumption of coffee may not be as bad as previous studies have portrayed.

BioMarin announced the investigative gene therapy reached pre-specified criteria for Factor VIII levels in adult patients with severe hemophilia A.

The signs and symptoms of the rare, chronic condition are not consistently detected in the first line of care.

Sleep apnea is associated with pulmonary, cardiovascular, psychiatric, neurologic, and weight-related effects. Primary care physicians need to monitor sleep health more.

Previous analyses into MultiStem Cell Therapy have shown benefits and safety in stroke patients. What will it take for the therapy to reach a phase 3 trial for ARDS?

Though the prostacyclin-targeting therapy selexipag is beneficial for PAH patients, investigators advise treatment to a trio of pathways.

Why are major adverse cardiovascular events not treated as the concern risk factors they are in patients with obstructive sleep apnea?

Upper airway stimulation, a sleep apnea treatment on the rise, is showing particular benefit for female patients.

Recent study found that having post-traumatic stress disorder, in and of itself, does not increase a patient's risk for cardiovascular disease. 

A 42-year-old female with no significant past medical history presents to the emergency department for two days of constant non-pleuritic, non-exertional, non-radiating chest pain associated with feeling light-headed. What is the diagnosis?

How new GRIPHON data showed further definitive long-term outcomes for patients with pulmonary hypertension.

Positive findings for the envelope support some of the first indications that a preventive measure could address cardiac surgery infection rates.

Teens and adults had similar weight loss after gastric bypass surgery, but teens were more likely to experience remission of type 2 diabetes and hypertension than adults.

Dalteparin sodium injection was shown to result in VTE resolution in a majority of treated patients from a clinical trial.

Thyroid hormones have a wide range of effects of the cardiovascular system. Too much or too little thyroiid hormones can induce or exacerbate existing cardiovascular disorders. In this article, we highlight the treatment recommendations for thyroid-related CVD events.

Investigators found that habitual glucosamine use was linked to lower risk of cardiovascular disease, coronary heart disease, and stroke.

Investigators found that patients with undiagnosed severe obstructive sleep apnea were at an increased risk of suffering a postoperative cardiovascular event.

Machine Learning algorithm analyzes 85 individual variables to determine a person's risk of having a heart attack or death with more than 90% accuracy.

The KardiaMobile 6L device is the first FDA-cleared 6-lead electrocardiogram (ECG) device for personal use.

A recent study found that 33.7% of patients on statins fail to lower their LDL-C to the recommended threshold of 100 mg per dL.